ACC's awards programs support the development of the next generation of clinicians and scientists, advance research and honor those who have made a difference in cardiology. Transforming ...

The Arrhythmias and Clinical EP Clinical Topic Collection gathers the latest guidelines, news, JACC articles, education, meetings and clinical images pertaining to its cardiovascular topical area — ...

The American College of Cardiology (ACC)'s Self-Assessment Programs (SAPs) are a suite of comprehensive, expert-developed, board-style educational and practice-assessment tools — with board-style ...

This page features ACC's full meeting coverage of the latest science from ACC.26, taking place March 28–30, 2026 in New Orleans, LA.

Spironolactone, an aldosterone blocker, compared with placebo, did not show any significant improvement in terms of heart failure (HF) hospitalizations and cardiovascular death at 24 months in ...

A newly released ACC Expert Consensus Decision Pathway (ECDP) focused on the clinical assessment, management and trajectory of patients hospitalized with heart failure (HF) includes revisions to the ...

Long-term melatonin use for insomnia was associated with a higher hazard of heart failure (HF), an increase in HF hospitalizations and a doubling of all-cause mortality over five years, according to a ...

The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing, along with the aging population and the ongoing rise in risk factors such as hypertension, ...

Erectile dysfunction (ED) is a risk marker of cardiovascular disease (CVD) and should be considered a risk-enhancing factor when considering the intensity of risk-factor reduction. Patients with ED ...

Interventional science was the focus of a Hot Line Session at ESC Congress 2026, with studies shedding light on milvexian with antiplatelet therapy following an acute coronary event; aspirin omission ...

A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...

The U.S. Food and Drug Administration (FDA) has approved baxdrostat, a first-in-class oral aldosterone synthase inhibitor, as an add-on therapy for hypertension in adults whose blood pressure (BP) is ...